Begrænset klinisk erfaring hos patienter, der samtidigt er inficerede med HIV og HBV, tyder på, at behandling med emtricitabin eller tenofovirdisoproxilfumarat i antiretroviral kombinationsbehandling til kontrol af HIV- infektion også resulterer i reduktion af HBV- DNA (henholdsvis 3 log10 reduktion eller 4- 5 log10 reduktion) (se pkt.
Patients coinfected with HIV and HBV: limited clinical experience in patients co-infected with HIV and HBV suggests that treatment with emtricitabine or tenofovir disoproxil fumarate in antiretroviral combination therapy to control HIV infection also results in a reduction in HBV DNA (3 log10 reduction or 4 to 5 log10 reduction, respectively) (see section 4.4).